BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang F, Sun S, Wang C, Haas M, Yeo S, Guan JL. Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation. Br J Cancer 2020;122:1791-802. [PMID: 32336756 DOI: 10.1038/s41416-020-0839-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chmielewska N, Wawer A, Osuch B, Maciejak P, Szyndler J. mTOR and HDAC2 are simultaneously activated during electrically induced kindling of seizures. Epilepsy Research 2022;185:106991. [DOI: 10.1016/j.eplepsyres.2022.106991] [Reference Citation Analysis]
2 Baker IM, Smalley JP, Sabat KA, Hodgkinson JT, Cowley SM. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs). Biochemistry 2022. [PMID: 35948047 DOI: 10.1021/acs.biochem.2c00288] [Reference Citation Analysis]
3 Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem 2021;226:113825. [PMID: 34562854 DOI: 10.1016/j.ejmech.2021.113825] [Reference Citation Analysis]
4 Ren Y, Wu S, Chen S, Burdette JE, Cheng X, Kinghorn AD. Interaction of (+)-Strebloside and Its Derivatives with Na+/K+-ATPase and Other Targets. Molecules 2021;26:5675. [PMID: 34577146 DOI: 10.3390/molecules26185675] [Reference Citation Analysis]
5 Ren Y, Wu S, Burdette JE, Cheng X, Kinghorn AD. Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation. Molecules 2021;26:3672. [PMID: 34208576 DOI: 10.3390/molecules26123672] [Reference Citation Analysis]